Harbour BioMed Reports Successful Phase I Trial of Autoimmune Treatment
publication date: Feb 21, 2020
Harbour BioMed, a Suzhou-Shanghai biopharma, reported that HBM916, a fully human anti-FcRn monoclonal antibody aimed at autoimmune disorders, showed an "excellent" safety profile in a Hong Kong Phase I study. The candidate also reduced IgC levels, its target, though HBM did not release specific data. HBM will begin clinical trials of HBM916 that enroll patients with several autoimmune diseases, including adult immune thrombocytopenia, myasthenia gravis, Grave’s ophthalmopathy and neuromyelitis optica spectrum disorder. In 2017, HBM acquired Greater Chins rights for two biologic drugs, including HBM916, from Korea's HanAll Biopharma in an $81 million deal. More details....
Stock Symbol: (KS: 009420)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.